Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 12, 2014 16:01 ET | Source: Revance Therapeutics, Inc

Revance Therapeutics Releases Third Quarter 2014 Results

– Confirmation of Plans to Initiate Phase 2 Active Comparator Study for RT002 in 2014 – – Updated Full Year 2014 Financial Guidance – NEWARK, Calif., Nov. 12, 2014 (GLOBE...
November 04, 2014 16:10 ET | Source: Revance Therapeutics, Inc

Revance Therapeutics, Inc. Announces Participation in Credit Suisse 2014 Healthcare Conference

NEWARK, Calif., Nov. 4, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic...
October 29, 2014 16:01 ET | Source: Revance Therapeutics, Inc

Revance Therapeutics to Release Third Quarter 2014 Financial Results and Host Conference Call on Wednesday, November 12, 2014

NEWARK, Calif., Oct. 29, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic...
October 01, 2014 16:01 ET | Source: Revance Therapeutics, Inc

Revance Therapeutics Provides Update on RT001 Clinical Program for the Lead Indication for Crow's Feet Lines

NEWARK, Calif., Oct. 1, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic...
September 22, 2014 16:10 ET | Source: Revance Therapeutics, Inc

Revance Therapeutics Announces the Appointment of Azita Nejad as Vice President of Quality

NEWARK, Calif., Sept. 22, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic...
September 02, 2014 16:10 ET | Source: Revance Therapeutics, Inc

Revance Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEWARK, Calif., Sept. 2, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic...
August 12, 2014 16:10 ET | Source: Revance Therapeutics, Inc

Revance Therapeutics Releases Second Quarter 2014 Financial Results

NEWARK, Calif., Aug. 12, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic...
August 12, 2014 16:01 ET | Source: Revance Therapeutics, Inc

Revance Therapeutics Appoints Industry Veteran Arthur P. Bertolino, M.D., Ph.D., M.B.A. as Chief Medical Officer

NEWARK, Calif., Aug. 12, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic...
July 29, 2014 16:02 ET | Source: Revance Therapeutics, Inc

Revance Therapeutics to Release Second Quarter 2014 Financial Results and Host Conference Call on Tuesday, August 12, 2014

NEWARK, Calif., July 29, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic...
June 24, 2014 16:05 ET | Source: Revance Therapeutics, Inc

Revance Therapeutics Announces Closing of Its Follow-on Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

NEWARK, Calif., June 24, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic...